[go: up one dir, main page]

ES2166379T3 - 2-aminotetralinas sustituidas. - Google Patents

2-aminotetralinas sustituidas.

Info

Publication number
ES2166379T3
ES2166379T3 ES94925190T ES94925190T ES2166379T3 ES 2166379 T3 ES2166379 T3 ES 2166379T3 ES 94925190 T ES94925190 T ES 94925190T ES 94925190 T ES94925190 T ES 94925190T ES 2166379 T3 ES2166379 T3 ES 2166379T3
Authority
ES
Spain
Prior art keywords
sub
aminotetralinas
replaced
hyperprolactinemia
parkinsonism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94925190T
Other languages
English (en)
Inventor
Mark C Sleevi
Gevork Minaskanian
L Meredith Moses
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Discovery Therapeutics Inc
Original Assignee
Discovery Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discovery Therapeutics Inc filed Critical Discovery Therapeutics Inc
Application granted granted Critical
Publication of ES2166379T3 publication Critical patent/ES2166379T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/12—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

COMPUESTOS ACTIVOS OPTICAMENTE O RACEMICOS REPRESENTADOS POR LA FORMULA (I) EN DONDE R{SUB,1}, R{SUB,2}, R{SUB,3}, R{SUB,5} Y N SON DEFINIDOS COMO EN LA ESPECIFICACION, Y SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS. ESTOS COMPUESTOS SON UTILES PARA ALIVIAR PARKINSONISMO, GLAUCOMA, HIPERPROLACTINEMIA Y PARA INDUCIR A LA PERDIDA DE PESO EN MAMIFEROS.
ES94925190T 1993-08-05 1994-08-05 2-aminotetralinas sustituidas. Expired - Lifetime ES2166379T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/102,436 US5382596A (en) 1993-08-05 1993-08-05 Substituted 2-aminotetralins

Publications (1)

Publication Number Publication Date
ES2166379T3 true ES2166379T3 (es) 2002-04-16

Family

ID=22289833

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94925190T Expired - Lifetime ES2166379T3 (es) 1993-08-05 1994-08-05 2-aminotetralinas sustituidas.

Country Status (11)

Country Link
US (1) US5382596A (es)
EP (1) EP0717620B1 (es)
JP (1) JP3839043B2 (es)
AT (1) ATE207745T1 (es)
AU (1) AU682388B2 (es)
CA (1) CA2168097C (es)
DE (1) DE69428903T2 (es)
DK (1) DK0717620T3 (es)
ES (1) ES2166379T3 (es)
PT (1) PT717620E (es)
WO (1) WO1995004532A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646188A (en) * 1995-07-05 1997-07-08 Teva Pharmaceutical Industries, Ltd. Polyamine derivatives of 1-aminoindan
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
PL202805B1 (pl) 1999-11-23 2009-07-31 Aderis Pharmaceuticals Sposób otrzymywania aminotetralin podstawionych azotem
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
SI1426049T1 (en) * 2002-12-02 2005-08-31 Sanol Arznei Schwarz Gmbh Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
WO2004091596A2 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
MX2010005925A (es) * 2007-11-28 2010-08-02 Ucb Pharma Gmbh Nueva forma polimorfico de rotigotina y proceso para la produccion.
IT1392387B1 (it) * 2008-09-26 2012-03-02 Solmag S P A Ora Fidia Farmaceutici S P A Processo per la preparazione di rotigotina
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
CN102010400B (zh) 2009-09-07 2015-02-04 药源药物化学（上海）有限公司 S-5-取代-n-2'-(噻吩-2-基-)乙基-1,2,3,4-四氢萘-2-胺或其手性酸盐和用于制备罗替戈汀
RS65853B1 (sr) 2009-12-22 2024-09-30 UCB Biopharma SRL Polivinilpirolidon za stabilizaciju čvrste disperzije nekristalnog oblika rotigotina
WO2011161255A2 (en) 2010-06-25 2011-12-29 Ucb Pharma Gmbh Novel process for the preparation of nitrogen substituted aminotetralins derivatives
BR112013033559A2 (pt) * 2011-06-27 2016-08-16 Shan Dong Luye Pharm Co Ltd método para industrialmente preparar amino-5,6,7,8-tetra-hidronaftol substituído de nitrogênio
CN114890978B (zh) * 2022-04-19 2023-07-25 宿迁医美科技有限公司 酚类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL298071A (es) * 1963-06-04
US3991207A (en) * 1971-03-18 1976-11-09 Pfizer Inc. Combination therapy for Parkinson's disease
CA1017359A (en) * 1972-07-03 1977-09-13 Frederic P. Hauck Substituted cyclic polymethylene phenols
US3930022A (en) * 1972-07-03 1975-12-30 Squibb & Sons Inc Certain tetrahydronaphthalenes used in the treatment of cardiac arrhythmia
US4267373A (en) * 1972-07-03 1981-05-12 E. R. Squibb & Sons, Inc. 5,6,7,8-Tetrahydronaphthalene hypotensive agents
US4057582A (en) * 1973-09-26 1977-11-08 Abbott Laboratories Aminotetralins and use in inducing anesthesia
JPS5826332B2 (ja) * 1974-04-25 1983-06-02 武田薬品工業株式会社 テトラロ−ルカゴウブツ ノ セイゾウホウ
DK254975A (da) * 1974-06-12 1975-12-13 Takeda Chemical Industries Ltd Fremgangsmade til fremstilling af aminotetralolforbindelser
DE3062971D1 (en) * 1979-09-14 1983-06-09 Sandoz Ag Derivatives of tetraline, their preparation and medicaments containing these compounds
US4564628A (en) * 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US4722933A (en) * 1985-12-20 1988-02-02 Nelson Research & Development Co. Substituted 2-aminotetralins
IT1224405B (it) * 1987-12-23 1990-10-04 Simes Composti attivi sul sistema cardiovascolare
DE3820775A1 (de) * 1988-06-20 1989-12-21 Thomae Gmbh Dr K Neue 4,5,7,8-tetrahydro-6h-thiazolo(5,4,-d)azepine, ihre herstellung und ihre verwendung als arzneimittel
EP0463119A4 (en) * 1989-07-05 1992-01-22 Whitby Research Incorporated Substituted 2-aminotetralins

Also Published As

Publication number Publication date
EP0717620A4 (en) 1997-05-28
JP3839043B2 (ja) 2006-11-01
DE69428903T2 (de) 2002-04-04
PT717620E (pt) 2002-04-29
DK0717620T3 (da) 2001-11-26
DE69428903D1 (de) 2001-12-06
CA2168097C (en) 2005-06-28
WO1995004532A1 (en) 1995-02-16
EP0717620A1 (en) 1996-06-26
AU682388B2 (en) 1997-10-02
AU7520794A (en) 1995-02-28
EP0717620B1 (en) 2001-10-31
ATE207745T1 (de) 2001-11-15
JPH09501434A (ja) 1997-02-10
US5382596A (en) 1995-01-17
CA2168097A1 (en) 1995-02-16

Similar Documents

Publication Publication Date Title
ES2166379T3 (es) 2-aminotetralinas sustituidas.
ES2113368T3 (es) Antagonistas de serotonina.
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
ES2161290T3 (es) Derivados de quinazolina.
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2138977T3 (es) Agonistas muscarinicos.
ES2150567T3 (es) Antagonistas del factor de liberacion de la corticotropina.
MX9307332A (es) 3-(aminoalquilamino)-1,2-bencisoxasoles substituidos y compuestos relacionados.
UY25230A1 (es) Derivados de la d-prolina
ES8507534A1 (es) Procedimiento para la preparacion de derivados benzopiranicos
ES2123873T3 (es) Pirrolocarbazol.
MX9400037A (es) Composicion oftalmica para el tratamiento de glaucoma e hipertension ocular.
ES2116496T3 (es) Proceso para la preparacion de 1,4-disubstituido-5(4h)-tetrazolinonas.
ES2029879T3 (es) Procedimiento para producir derivados de aminas sustituidas.
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
ES2182090T3 (es) Nuevos derivados de pirrol.
ATE196464T1 (de) Benzol-derivate, verwendbar für ischämische erkrankungen
ES2081834T3 (es) Pirrolidin-2-onas 4-metil y 4-etil sustituidas.
ES2158290T3 (es) Derivados de tiazolidinona opticamente activos.
ES2130548T3 (es) Nuevos derivados alquil-amino-indanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2038159T3 (es) Procedimiento para preparar derivados sustituidos de 2-aminoacetamida.
NO880143L (no) Soetemiddel.
UA26443A (uk) Похідhі 20,21-диhоребурhамеhіhу, їх рацемати або оптичhі ізомери, або їх адитивhі солі з оргаhічhими кислотами, що мають hоотропhі та аhтидепресивhі властивості
ES2052825T3 (es) Derivados de cicloalquiltiazol.
ES2079531T3 (es) 3-(1,2-bencisoxazol-3-il)-4-piridinaminas y derivados.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 717620

Country of ref document: ES